AMGEN INC

The company operates in the biotechnology and pharmaceutical sector, focusing on the discovery, development, and delivery of innovative therapies. Its primary offerings include treatments such as Prolia, Repatha, Otezla, Enbrel, Evenity, Xgeva, Tepezza, Blincyto, Nplate, Tezspire, Kyprolis, Aranesp, Krystexxa, and Vectibix. Revenue is predominantly derived through a specialized product segment alongside related technology rights and collaborative agreements. The enterprise serves patients and healthcare institutions, directing sales largely through major regional distribution networks and wholesale customers.

Operations and commercial sales extend across the United States as well as diverse international locations. Physical assets and operational presences are established in territories such as the United States, Puerto Rico, and Ireland, spanning dedicated manufacturing facilities, research laboratories, and administrative properties. The organization coordinates its activities across these global sites to facilitate product distribution, ongoing research, and large-scale manufacturing infrastructure.

Summary of the business section of Amgen's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, Amgen had approximately 31,500 staff members in over 50 countries, including approximately 13,000 staff members outside the United States, and we continue to experience overall low turnover rates.”